NASDAQ:NTLA
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc.'s revenue grew 16.9% in fiscal 2025 to $67.7M while operating margin rose to −651.7%. Free cash flow was −$395.9M, −585.0% of revenue, and the diluted share count rose 9.6%.Summary generated from Intellia Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$67.7M
Revenue growth+16.9%
Revenue, 5-yr CAGR+3.1%
Gross marginn/a
Operating margin−651.7%
Net margin−609.9%
ROICn/a
Return on equity−53.5%
Debt / equityn/a
Free cash flow−$395.9M
FCF margin−585.0%
Share count change+9.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 33 | 52 | 36 | 58 | 68 |
| Operating income | −268 | −458 | −515 | −534 | −441 |
| Net income | −268 | −474 | −481 | −519 | −413 |
| Free cash flow | −238 | −347 | −408 | −355 | −396 |
Recent filings
- 4Insider transaction report
Oct 6, 2026 - 8-KRegulation FD disclosure
Sep 8, 2026 - 8-KEntry into a material agreement
Sep 4, 2026 - 4Insider transaction report
Aug 24, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KRegulation FD disclosure
Jun 15, 2026 - 8-KResults of a shareholder vote
Jun 10, 2026